Amplo Biotechnology, Inc.
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $4.0Mattributed |
|---|---|
| Latest round | grant, $3.0M, 2024-01-01attributed |
| Founded | 2019 |
| Headquarters | Towson, Maryland |
| Industry | bio |
| Stage | unknown |
| Website | amplobiotechnology.com |
AAV gene therapy biotech focused on diseases of the neuromuscular junction. Targets pharma partners and patients with congenital myasthenic syndromes and related rare neuromuscular disorders. Differentiates with leads AMP-101 (Dok-7) and AMP-201 (Collagen-Q) and a tightly-focused indication scope advised by NMJ experts.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $3.0M | undisclosed |
Detected tech stack
Cloudflare, Cloudflare Bot Management
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $3.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $4.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | amplobiotechnology.com, read 2026-05-02 |
| Description | self-reported | amplobiotechnology.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.